On February 19, 2016, Jeffrey F. Eisenberg, 50, was appointed to serve as a member of the Board of Directors of MabVax Therapeutics Holdings, Inc. (the "Company"). From 2009 to January 2016 Mr. Eisenberg served as President, Chief Executive Officer and board member of Noven Pharmaceuticals, Inc. Noven develops, manufactures and markets prescription pharmaceuticals, with a specialty in transdermal drug delivery systems. Noven is the U.S. prescription pharmaceutical division of Hisamitsu Pharmaceutical Inc., a Japanese pharmaceutical company and the world's largest manufacturer of transdermal drug patches.

Mr. Eisenberg had been part of Noven's senior management team since 1998, having previously served as Executive Vice President, Senior Vice President - Strategic Alliances, and as the company's General Counsel and Corporate Secretary. Mr. Eisenberg also served as President of Novogyne Pharmaceuticals, a Women's Health commercial joint venture between Noven and Novartis Pharmaceuticals Corporation. Mr. Eisenberg has significant experience in the area of corporate transactions and strategic alliances, product development, commercialization, manufacturing and talent management. In addition, he led the post-acquisition integration of JDS Pharmaceuticals, a private specialty pharmaceutical company purchased by Noven in 1997, as well as the integration of Noven and Hisamitsu following the acquisition of Noven.

Mr. Eisenberg is an expert in corporate governance, having advised the boards of IVAX, Noven and others through a number of significant internal and external issues, including mergers and acquisitions, corporate financings, strategic alliances, CEO transitions, securities class action lawsuits, FDA warning letters and consent decrees, and development and implementation of corporate governance policies.

Mr. Eisenberg holds a BS in Economics from the Wharton School of the University of Pennsylvania, and a JD from Columbia University Law School.
In connection with his appointment, Mr. Eisenberg received a non-qualified option to purchase up to 50,000 shares of MabVax common stock at an exercise price of $0.50 and will be eligible to receive the cash compensation described in the Company's Non Employee Director Compensation Policy, namely an annual cash retainer of $28,000 paid quarterly.

Mr. Eisenberg was appointed on the nomination, and with the consent, of OPKO Health Inc., under a letter agreement with the Company dated as of June 30, 2015. In connection with the appointment of Mr. Eisenberg, the Board increased the number of directors constituting the whole Board from 7 to 8.

Press Release
In connection with the items disclosed in this Current Report, MabVax issued the press release attached to this Current Report as Exhibit 99.1 on February 25, 2016.

Press Release of the Company dated February 25, 2016